Bristol-Myers, Celgene and The Perils Of The US Drug Pricing Environment
Bristol-Myers, Celgene and The Perils Of The US Drug Pricing Environment
$131.00
Pink Sheet brings you a look at the effects of the Bristol-Celgene merger on the public and political perceptions of the companies, with an examination of how pricing for Revlimid has affected Celgene’s public image and stock pricing.
Author: Cathy Kelly
Publisher: Pinksheet
- Description
In a bid to expand their immunology and oncology footprint, Bristol-Myers is set to purchase Celgene for $74bn. Pink Sheet’s expert industry analysts examine the effects of Celgene’s pricing strategies – specifically for its blockbuster Revlimid, for the treatment of multiple myeloma – on public perception of the company, and its negative effects on investor behavior and stock prices. Pink Sheet also examines the effect of pricing and payment in regards to Medicare Part D for drugs similar to the Revlimid profile as well as additional drugs.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
The Next New Thing In FDA Inspections: Poor Root Cause Investigations 
Sign up to the